Publications

Journal Article
Review
Epublish 247 citations
Open access — free full text available
Open access
Electronic publication date
March 3, 2015

View on Pubmed.gov 25729364 | View on doi.org 10.3389/fphar.2... | View the free full text Full text

Advantages and applications of CAR-expressing natural killer cells.

Search for publications in this journal Front Pharmacol

Abstract

In contrast to donor T cells, natural killer (NK) cells are known to mediate anti-cancer effects without the risk of inducing graft-versus-host disease (GvHD). In order to improve cytotoxicity against resistant cancer cells, auspicious efforts have been made with chimeric antigen receptor (CAR) expressing T- and NK cells. These CAR-modified cells express antigen receptors against tumor-associated surface antigens, thus redirecting the effector cells and enhancing tumor-specific immunosurveillance. However, many cancer antigens are also expressed on healthy tissues, potentially leading to off tumor/on target toxicity by CAR-engineered cells. In order to control such potentially severe side effects, the insertion of suicide genes into CAR-modified effectors can provide a means for efficient depletion of these cells. While CAR-expressing T cells have entered successfully clinical trials, experience with CAR-engineered NK cells is mainly restricted to pre-clinical investigations and predominantly to NK cell lines. In this review we summarize the data on CAR expressing NK cells focusing on the possible advantage using these short-lived effector cells and discuss the necessity of suicide switches. Furthermore, we address the compliance of such modified NK cells with regulatory requirements as a new field in cellular immunotherapy.

References

PLoS One. 2011;6(11):e27351

Mol Ther. 2014 Sep;22(9):1564-74

Blood. 2009 Jun 11;113(24):6094-101

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-6

Cited by 247 citations (total)

Journal Article

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

Electronic publication date October 25, 2017

Search for publications in this journal Leukemia

K H Chen [...] Y Ma et al.

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy...

Journal Article

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.

Electronic publication date December 26, 2017

Search for publications in this journal Methods Mol Biol

Martin Felices [...] Daniel A Vallera et al.

Cancer immunotherapies have gained significant momentum over the past decade, particularly with the advent of checkpoint inhibitors and CAR T-cells....

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties